Analyst: Arzerra is a break-even project for Genmab
Sales of the Genmab-developed drug Arzerra are in decline, but analyst Thomas Bowers expects them to rise again later in the year, just as there is a possibility of a genuine rebirth in the long run.
BY STEFAN SINGH KAILAY
The last two quarters have shown declining sales numbers for the Genmab-developed cancer drug Arzerra, which is marketed by GlaxoSmithKline. But the recent development does not surprise Danske Bank’s pharmaceutical sector analyst, Thomas Bowers.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Arzerra outperformed by business partner
For abonnenter
“This is a huge disappointment in my career”
For abonnenter
Genmab CEO: A year focused on daratumumab
For abonnenter
